WEBVTT - Miracle Drugs, Million Dollar Price Tags

0:00:00.160 --> 0:00:02.400
<v Speaker 1>I got the little vial out and it's just like

0:00:02.560 --> 0:00:08.719
<v Speaker 1>five milliliters of liquid gold. You know, it wasn't in

0:00:08.760 --> 0:00:11.640
<v Speaker 1>the bottle because it was inside of our son. But

0:00:11.760 --> 0:00:15.640
<v Speaker 1>I was just looking at that little bottle and teary eyed,

0:00:15.880 --> 0:00:19.360
<v Speaker 1>you know, like, oh my goodness, it's so small, and

0:00:19.440 --> 0:00:23.640
<v Speaker 1>yet it's been so big in our lives. And how

0:00:23.680 --> 0:00:26.440
<v Speaker 1>do you put a price on that? I don't know.

0:00:27.720 --> 0:00:31.520
<v Speaker 2>This is Cheryl Yoda. The liquid gold she's referring to

0:00:31.840 --> 0:00:35.040
<v Speaker 2>is a medication called nusan Erson that saved the life

0:00:35.040 --> 0:00:36.640
<v Speaker 2>of her eight year old son, Jace.

0:00:37.560 --> 0:00:40.560
<v Speaker 1>His big thing right now is hunting. We've literally gotten

0:00:40.680 --> 0:00:43.280
<v Speaker 1>up and he's been out for like an hour stalking

0:00:43.320 --> 0:00:45.480
<v Speaker 1>around the backyard with his bow and arrow.

0:00:45.920 --> 0:00:48.480
<v Speaker 2>He's practicing for when he's old enough to go deer

0:00:48.560 --> 0:00:51.720
<v Speaker 2>hunting with his dad and big brothers. But back when

0:00:51.800 --> 0:00:54.800
<v Speaker 2>Jace was a baby, Cheryl didn't think anything like that

0:00:54.840 --> 0:00:58.160
<v Speaker 2>would ever be possible for him. When Jace was eight

0:00:58.240 --> 0:01:02.240
<v Speaker 2>days old, he was diagnosed with rare genetic disease called SMA,

0:01:02.960 --> 0:01:07.760
<v Speaker 2>or spinal muscular atrophy. SMA interferes with the brain's ability

0:01:07.800 --> 0:01:11.840
<v Speaker 2>to communicate with muscles over time. People with the most

0:01:11.880 --> 0:01:15.800
<v Speaker 2>severe form of the disease like Jace lose the ability

0:01:15.880 --> 0:01:20.120
<v Speaker 2>to swallow and breathe. Doctors told Cheryl it was unlikely

0:01:20.240 --> 0:01:25.240
<v Speaker 2>Jace would live to see his second birthday. Sadly, Cheryl

0:01:25.280 --> 0:01:29.520
<v Speaker 2>was already familiar with SMA before Jace. She'd given birth

0:01:29.560 --> 0:01:33.320
<v Speaker 2>to two boys who didn't have SMA and a daughter, Ariel,

0:01:33.520 --> 0:01:37.160
<v Speaker 2>who did. Ariel died when she was fifteen months old,

0:01:37.920 --> 0:01:42.720
<v Speaker 2>and after learning about Jace's diagnosis, she thought he would too.

0:01:42.880 --> 0:01:46.920
<v Speaker 1>It just felt like he had received basically a death sentence,

0:01:46.920 --> 0:01:50.120
<v Speaker 1>and we were going to kind of enjoy him for

0:01:50.200 --> 0:01:52.360
<v Speaker 1>a year and a half to two years and then

0:01:53.320 --> 0:01:55.760
<v Speaker 1>try to help him be as happy and comfortable and

0:01:55.840 --> 0:01:58.240
<v Speaker 1>have a great life as he could, and then have

0:01:58.320 --> 0:01:59.320
<v Speaker 1>to say goodbye to him.

0:02:00.400 --> 0:02:03.600
<v Speaker 2>Jace's doctor gave Cheryl a referral to see a pediatric

0:02:03.640 --> 0:02:08.440
<v Speaker 2>neurologist at Johns Hopkins University School of Medicine. At the appointment,

0:02:08.639 --> 0:02:12.000
<v Speaker 2>Cheryl says, the doctor gave Jason an exam and then

0:02:12.040 --> 0:02:14.359
<v Speaker 2>asked her and her husband how soon they could get

0:02:14.360 --> 0:02:19.000
<v Speaker 2>on an aeroplane. The doctor explained there was a clinical

0:02:19.040 --> 0:02:21.600
<v Speaker 2>trial getting started for a drug that might be able

0:02:21.680 --> 0:02:25.520
<v Speaker 2>to stop the symptoms of SMA from ever starting, and

0:02:25.760 --> 0:02:29.240
<v Speaker 2>he said Jace would be a perfect candidate since he

0:02:29.360 --> 0:02:34.320
<v Speaker 2>was still presymptomatic, but there were only twenty five spots open.

0:02:34.760 --> 0:02:36.920
<v Speaker 2>They'd need to act fast and get to one of

0:02:36.960 --> 0:02:40.280
<v Speaker 2>the research sites in a matter of days. Cheryl and

0:02:40.320 --> 0:02:43.400
<v Speaker 2>her husband left the appointment completely shocked.

0:02:44.160 --> 0:02:47.320
<v Speaker 1>Just feeling like we had received a gift a lake

0:02:48.000 --> 0:02:52.560
<v Speaker 1>instead of walking out there with with options alike. You know,

0:02:52.760 --> 0:02:54.560
<v Speaker 1>when do you want Haspers to come out.

0:02:54.440 --> 0:02:55.040
<v Speaker 3>And visit you?

0:02:55.280 --> 0:02:58.360
<v Speaker 1>That kind of thing we were talking about him living.

0:03:01.440 --> 0:03:04.519
<v Speaker 2>They flew from Baltimore to Chicago later that week, where

0:03:04.600 --> 0:03:08.919
<v Speaker 2>Jace was screened for the clinical trial and selected. Jace

0:03:09.040 --> 0:03:12.160
<v Speaker 2>was given four doses of new Sinerson over the course

0:03:12.200 --> 0:03:15.560
<v Speaker 2>of a few weeks. Cheryl learned that he'd need another

0:03:15.639 --> 0:03:19.679
<v Speaker 2>dose every four months, probably for the rest of his life.

0:03:19.880 --> 0:03:22.040
<v Speaker 2>By the time Jace was one and a half in

0:03:22.120 --> 0:03:26.799
<v Speaker 2>December twenty sixteen, he still wasn't showing any SMA symptoms.

0:03:27.440 --> 0:03:32.520
<v Speaker 2>Cheryl was overjoyed. Then, two days before Christmas, the rest

0:03:32.560 --> 0:03:36.640
<v Speaker 2>of the SMA community rejoiced too. New Sinerson was approved

0:03:36.680 --> 0:03:39.920
<v Speaker 2>by the FDA. That meant the drug treatment would become

0:03:39.960 --> 0:03:43.440
<v Speaker 2>available to more people, even if they weren't enrolled in

0:03:43.480 --> 0:03:51.360
<v Speaker 2>a clinical trial, But one week later, the joy turned

0:03:51.400 --> 0:03:56.120
<v Speaker 2>to outrage. Biogen, the drug company that manufactures the drug,

0:03:56.440 --> 0:04:00.400
<v Speaker 2>issued an announcement of its own. The drugs trade name

0:04:00.440 --> 0:04:03.920
<v Speaker 2>would be spin Raza, they said, and it would cost

0:04:04.160 --> 0:04:07.720
<v Speaker 2>one hundred and twenty five thousand dollars per dose.

0:04:08.640 --> 0:04:12.080
<v Speaker 1>I mean, now I pay anything, But then how can

0:04:12.120 --> 0:04:16.040
<v Speaker 1>I pay anything? Like, how do I pay one hundred

0:04:16.040 --> 0:04:19.440
<v Speaker 1>and twenty five thousand dollars a dose? Just get that

0:04:19.560 --> 0:04:21.920
<v Speaker 1>out three times a year? That's impossible.

0:04:22.400 --> 0:04:26.880
<v Speaker 2>At the time, Cheryl considered herself fortunate. Jase's costs was

0:04:26.920 --> 0:04:30.480
<v Speaker 2>still being covered by the clinical trial, and the clinical

0:04:30.560 --> 0:04:34.920
<v Speaker 2>trial kept getting extended and extended, but eventually it came

0:04:34.960 --> 0:04:38.000
<v Speaker 2>to an end. Earlier this year when Jace turned.

0:04:37.839 --> 0:04:41.880
<v Speaker 1>Eight, and I did have those thoughts like, oh my goodness,

0:04:42.120 --> 0:04:45.080
<v Speaker 1>now what Like I need to get on the ball

0:04:45.160 --> 0:04:48.839
<v Speaker 1>and start researching. Maybe there are other studies we could

0:04:48.880 --> 0:04:51.360
<v Speaker 1>be in. I need to talk to our insurance and

0:04:51.400 --> 0:04:54.120
<v Speaker 1>find out if they'll cover this drug and that kind

0:04:54.160 --> 0:04:59.360
<v Speaker 1>of thing. And I just started feeling overwhelmed, like I'm

0:04:59.360 --> 0:05:03.359
<v Speaker 1>not that sad, I'm not that organized. How am I

0:05:03.520 --> 0:05:04.599
<v Speaker 1>ever going to do all of this?

0:05:07.800 --> 0:05:11.359
<v Speaker 2>I'm Laurena Rora Hutchinson. I'm the director of the Ideas

0:05:11.440 --> 0:05:16.440
<v Speaker 2>Lab at the Johns Hopkins Berman Institute of Bioethics. In

0:05:16.480 --> 0:05:21.000
<v Speaker 2>today's episode, Miracle Drugs, Modern medicine has been on the

0:05:21.040 --> 0:05:25.200
<v Speaker 2>cusp of a revolution for years. There's a growing list

0:05:25.240 --> 0:05:28.080
<v Speaker 2>of drugs that can save lives and cure diseases like

0:05:28.279 --> 0:05:33.119
<v Speaker 2>never before. But the price for these medications can reach

0:05:33.240 --> 0:05:37.880
<v Speaker 2>six and even seven figures, raising high stakes ethical questions

0:05:37.920 --> 0:05:43.200
<v Speaker 2>about access and regulation from Pushkin Industries and the Johns

0:05:43.200 --> 0:05:54.039
<v Speaker 2>Hopkins Berman Institute of Bioethics. This is playing God. Jays

0:05:54.080 --> 0:05:57.640
<v Speaker 2>got his first commercial dose of Spinraza this year, and

0:05:57.760 --> 0:06:01.520
<v Speaker 2>Cheryl's insurance company covered the cost, but that's not how

0:06:01.560 --> 0:06:04.400
<v Speaker 2>it works for all families. It can be a real

0:06:04.480 --> 0:06:08.400
<v Speaker 2>issue getting insurance companies to cover high cost drugs like spinraza.

0:06:09.240 --> 0:06:12.560
<v Speaker 2>Even when they do, there's no guarantee coverage will last.

0:06:13.240 --> 0:06:16.719
<v Speaker 4>The best day of my career was December twenty third,

0:06:16.760 --> 0:06:20.200
<v Speaker 4>twenty sixteen, when the drug was licensed by the FDA.

0:06:21.320 --> 0:06:23.800
<v Speaker 4>The worst day of my career was December twenty seventh,

0:06:23.839 --> 0:06:26.440
<v Speaker 4>twenty sixteen, when the price was announced.

0:06:27.160 --> 0:06:31.200
<v Speaker 2>Tom Crawford is a pediatric neurologist at Johns Hopkins University

0:06:31.279 --> 0:06:34.960
<v Speaker 2>School of Medicine. He's been caring for children with spinal

0:06:35.080 --> 0:06:39.120
<v Speaker 2>muscular atrophy for over thirty years, and he's very familiar

0:06:39.160 --> 0:06:42.839
<v Speaker 2>with the challenges his patient's face. It was Tom who

0:06:42.839 --> 0:06:45.680
<v Speaker 2>told Cheryls she should try to get jase enrolled in

0:06:45.680 --> 0:06:46.159
<v Speaker 2>the trial.

0:06:46.800 --> 0:06:49.560
<v Speaker 4>I couldn't you know. I was over the top. Oh

0:06:49.560 --> 0:06:51.360
<v Speaker 4>my god, we have this therapy. It's going to work.

0:06:51.360 --> 0:06:53.720
<v Speaker 4>And then four days later, one hundred and twenty five

0:06:53.760 --> 0:06:56.760
<v Speaker 4>thousand dollars a dose, six doses for the first year

0:06:56.760 --> 0:06:59.520
<v Speaker 4>of life, three doses every year thereafter. Oh my god,

0:06:59.680 --> 0:07:01.600
<v Speaker 4>none of our patients are ever ever going to be

0:07:01.640 --> 0:07:03.719
<v Speaker 4>able to pay for it. It's been snatched away from

0:07:03.720 --> 0:07:07.160
<v Speaker 4>me in all my patients. Then I learned that the

0:07:07.240 --> 0:07:09.800
<v Speaker 4>drug companies were really, really smart. They realized that that

0:07:09.960 --> 0:07:13.320
<v Speaker 4>no insurance company is going to let a baby die

0:07:13.480 --> 0:07:15.360
<v Speaker 4>for one hundred and twenty five thousand dollars, and they

0:07:15.400 --> 0:07:21.480
<v Speaker 4>would approve the authorization. And so what the new barrier

0:07:22.160 --> 0:07:25.520
<v Speaker 4>is now not just the price, but the authorization's getting

0:07:26.160 --> 0:07:29.760
<v Speaker 4>the insurance companies to realize that this child is indeed

0:07:29.840 --> 0:07:33.720
<v Speaker 4>eligible and falls into the criteria that were used to

0:07:34.080 --> 0:07:37.040
<v Speaker 4>prove that it works. But now there's a whole game

0:07:37.080 --> 0:07:41.760
<v Speaker 4>going on because insurance companies will try to not authorize

0:07:41.760 --> 0:07:45.200
<v Speaker 4>if possible, if the child's not exactly in the group

0:07:45.240 --> 0:07:47.760
<v Speaker 4>of patients than which the experiment was on, they'll say

0:07:47.800 --> 0:07:52.320
<v Speaker 4>it's an unproven therapy, and frankly, they're right, because we

0:07:52.560 --> 0:07:55.240
<v Speaker 4>proved it on a very narrow group of kids that

0:07:55.440 --> 0:07:57.960
<v Speaker 4>in which the benefit could be seen as quickly as possible,

0:07:57.960 --> 0:08:00.520
<v Speaker 4>because we wanted to get the drug out, And so

0:08:01.400 --> 0:08:05.440
<v Speaker 4>the shift in getting drugs to patients that would make

0:08:05.440 --> 0:08:09.280
<v Speaker 4>a difference to them has now shifted from science to

0:08:09.960 --> 0:08:15.880
<v Speaker 4>clinical authorizations and letters and pleadings and newspaper articles. This

0:08:15.920 --> 0:08:18.000
<v Speaker 4>is a different landscape than I would have ever imagined.

0:08:18.800 --> 0:08:20.520
<v Speaker 2>So I'd like to just zoom out here and cover

0:08:20.600 --> 0:08:23.360
<v Speaker 2>some of the basics. For people that don't really know

0:08:23.360 --> 0:08:26.720
<v Speaker 2>anything about SMA, could you just tell us what sm is.

0:08:27.080 --> 0:08:30.520
<v Speaker 4>Spinal muskro atrophy is a rare disease, but it's more

0:08:30.720 --> 0:08:34.800
<v Speaker 4>common than people realize. It's actually, before these new therapies,

0:08:34.920 --> 0:08:38.040
<v Speaker 4>was the most common genetic cause of death and infants

0:08:38.320 --> 0:08:42.040
<v Speaker 4>that would kill about one in ten thousand babies. It

0:08:42.040 --> 0:08:46.400
<v Speaker 4>affects all children of all races around the world with

0:08:46.600 --> 0:08:50.840
<v Speaker 4>roughly equal prevalence. It's a disease that affects essentially the

0:08:50.880 --> 0:08:54.240
<v Speaker 4>motor system, the muscles, and so babies who are born

0:08:54.320 --> 0:08:58.040
<v Speaker 4>with it look normal initially for the most part, and

0:08:58.080 --> 0:09:00.559
<v Speaker 4>then somewhere around two three four months of age, they

0:09:00.559 --> 0:09:02.760
<v Speaker 4>start to get weaker and weaker and weaker, to the

0:09:02.800 --> 0:09:06.000
<v Speaker 4>point where the muscles of breathing no longer work. As

0:09:06.040 --> 0:09:09.439
<v Speaker 4>near as we can tell, they are completely normal cognitively,

0:09:10.600 --> 0:09:13.720
<v Speaker 4>and it's a genetic disease, but it's a recessive genetic disease,

0:09:13.880 --> 0:09:16.600
<v Speaker 4>so when it happens, they don't have a family history.

0:09:16.600 --> 0:09:19.640
<v Speaker 4>For the most part, it's a surprise, and it comes

0:09:19.640 --> 0:09:23.000
<v Speaker 4>because both parents were carriers for it. The other thing

0:09:23.040 --> 0:09:26.520
<v Speaker 4>that's kind of interesting about SMA is that it exists

0:09:26.520 --> 0:09:30.560
<v Speaker 4>for some complicated genetic reasons across the spectrum, so that

0:09:30.640 --> 0:09:32.640
<v Speaker 4>there are the babies two thirds of them are the

0:09:32.640 --> 0:09:35.439
<v Speaker 4>babies that are going to succumb by twelve or fifteen

0:09:35.480 --> 0:09:39.040
<v Speaker 4>months of age, but the other third are milder forms

0:09:39.440 --> 0:09:41.600
<v Speaker 4>that show up a little bit later and are milder,

0:09:41.760 --> 0:09:45.000
<v Speaker 4>and at the mildest end you have adults who are

0:09:45.120 --> 0:09:48.559
<v Speaker 4>troubled by the fact that they can't go upstairs as

0:09:48.600 --> 0:09:50.760
<v Speaker 4>well as they would want to otherwise. So it's an

0:09:50.800 --> 0:09:56.120
<v Speaker 4>absolutely continuous spectrum of decreasing instance to milder and milder expression.

0:09:58.360 --> 0:10:00.960
<v Speaker 2>So could you tell me about y connection to Jace

0:10:01.040 --> 0:10:01.959
<v Speaker 2>and Cheryl Yoda.

0:10:02.480 --> 0:10:05.880
<v Speaker 4>Jace and his mom are my friends now. I first

0:10:06.000 --> 0:10:10.240
<v Speaker 4>met Cheryl and jeremy mom and dad when I cared

0:10:10.280 --> 0:10:13.400
<v Speaker 4>for the first baby, Ariel, and I have over here

0:10:13.640 --> 0:10:16.120
<v Speaker 4>a picture of Ariel. She lived to be fifteen months

0:10:16.120 --> 0:10:19.480
<v Speaker 4>of age, and we did the best possible. A few

0:10:19.559 --> 0:10:23.440
<v Speaker 4>years later, Jace was born and so they brought him

0:10:23.440 --> 0:10:25.640
<v Speaker 4>to me to see if this is what he had

0:10:25.760 --> 0:10:27.839
<v Speaker 4>or not. It was right around that time that we

0:10:27.840 --> 0:10:30.320
<v Speaker 4>were opening up a clinical trial of one of the

0:10:30.360 --> 0:10:34.840
<v Speaker 4>new therapies called Spinoza now, and he was my first patient.

0:10:35.120 --> 0:10:38.440
<v Speaker 4>So he got the dose, and I have a picture

0:10:38.559 --> 0:10:41.240
<v Speaker 4>here as well. I'm looking at the most amazing day

0:10:41.280 --> 0:10:44.040
<v Speaker 4>of my career. He was four months old and it

0:10:44.120 --> 0:10:47.880
<v Speaker 4>was clear that he was getting stronger, not weaker, and

0:10:47.920 --> 0:10:50.240
<v Speaker 4>it was one of the most goosebump moments of my

0:10:50.880 --> 0:10:55.480
<v Speaker 4>entire life, like, we have a cure for a disease

0:10:55.520 --> 0:10:58.040
<v Speaker 4>that used to kill babies, And so Jace over the

0:10:58.120 --> 0:11:00.600
<v Speaker 4>years has gotten stronger and stronger, and it's still for

0:11:00.679 --> 0:11:03.280
<v Speaker 4>me one of these goosebump moments to interact with him

0:11:03.280 --> 0:11:05.760
<v Speaker 4>because he's alive. Oh my god.

0:11:05.960 --> 0:11:06.560
<v Speaker 2>Yeah.

0:11:06.800 --> 0:11:11.360
<v Speaker 4>I was taking care of babies that lose and now

0:11:11.520 --> 0:11:15.200
<v Speaker 4>after this therapy, I get to be the person who

0:11:15.480 --> 0:11:19.440
<v Speaker 4>helps them not And no one could ever imagine a

0:11:19.480 --> 0:11:23.120
<v Speaker 4>career that goes from that to where we are now.

0:11:24.040 --> 0:11:27.520
<v Speaker 4>It's a feeling, an unbelieval ecstasy that we can We

0:11:27.640 --> 0:11:30.480
<v Speaker 4>don't have to do that anymore. I'm not burying babies.

0:11:31.960 --> 0:11:32.240
<v Speaker 1>Wow.

0:11:32.400 --> 0:11:36.240
<v Speaker 2>What an incredible shift. So I understand your research on

0:11:36.280 --> 0:11:39.960
<v Speaker 2>how SMA works was crucial for developing the miracle drugs

0:11:40.000 --> 0:11:43.080
<v Speaker 2>bin Rauser, as well as other drugs for SMA, and

0:11:43.120 --> 0:11:46.600
<v Speaker 2>you were instrumental in designing the clinical trial to test spinraser.

0:11:47.000 --> 0:11:48.319
<v Speaker 2>Could you tell me more about that.

0:11:49.000 --> 0:11:52.719
<v Speaker 4>Yeah. So I had the privilege of being carrying for

0:11:52.920 --> 0:11:55.679
<v Speaker 4>kids with SMA from the very beginning. I was very

0:11:55.720 --> 0:11:59.160
<v Speaker 4>much involved in designing the clinical trials and the outcome

0:11:59.160 --> 0:12:03.280
<v Speaker 4>measures necess to do the clinical trials. And then when

0:12:03.320 --> 0:12:05.920
<v Speaker 4>we had this first idea with spin raza, I was

0:12:05.960 --> 0:12:09.640
<v Speaker 4>the lead investigator here at Hopkins to give the drug

0:12:09.679 --> 0:12:11.560
<v Speaker 4>and then follow how well, they do and see if

0:12:11.559 --> 0:12:14.840
<v Speaker 4>there's any complications of it, and we've since studied quite

0:12:14.880 --> 0:12:17.040
<v Speaker 4>a number beyond that to show that it has a

0:12:17.080 --> 0:12:20.720
<v Speaker 4>broader effect and its benefit for this and the other

0:12:20.800 --> 0:12:21.680
<v Speaker 4>drugs for SME.

0:12:22.559 --> 0:12:25.120
<v Speaker 2>So, can you describe how drugs like spinraza work.

0:12:25.679 --> 0:12:30.400
<v Speaker 4>Spin Rasa and the other therapies are high end therapies

0:12:30.400 --> 0:12:34.680
<v Speaker 4>that are really designer for a very very specific mutation

0:12:34.960 --> 0:12:38.760
<v Speaker 4>in a specific genetic defect, and as such a high

0:12:38.800 --> 0:12:41.000
<v Speaker 4>effect therapy for rare disease.

0:12:41.440 --> 0:12:43.760
<v Speaker 2>What sort of diseases can these therapies treat?

0:12:44.880 --> 0:12:49.440
<v Speaker 4>Well? Right now they're targeting these mostly rare disorders, but

0:12:49.559 --> 0:12:53.120
<v Speaker 4>we can imagine targeting many of the named diseases like

0:12:53.200 --> 0:12:57.640
<v Speaker 4>cystic fibrosis or sickle cell disease or hemophilia. There's also

0:12:57.920 --> 0:13:01.920
<v Speaker 4>the promise that we can extend this to extremely rare diseases,

0:13:01.960 --> 0:13:04.600
<v Speaker 4>things that affect only a few people in the world

0:13:04.640 --> 0:13:07.040
<v Speaker 4>at a time. And so when we know the mutation,

0:13:07.800 --> 0:13:10.720
<v Speaker 4>there's the future prospect that we can design a drug

0:13:10.800 --> 0:13:15.840
<v Speaker 4>for that mutation in that patient, which is just abtolutely awesome.

0:13:16.360 --> 0:13:17.960
<v Speaker 4>It used to be the idea that we had to

0:13:18.040 --> 0:13:21.320
<v Speaker 4>understand why a disease happened and now it looks like

0:13:21.360 --> 0:13:23.760
<v Speaker 4>we have therapiest where we can skip over that step

0:13:24.160 --> 0:13:28.559
<v Speaker 4>and repair or replace the specific abdamality at the very

0:13:28.640 --> 0:13:33.120
<v Speaker 4>start by supplying something that was missing or undermining something

0:13:33.160 --> 0:13:34.160
<v Speaker 4>that's doing damage.

0:13:34.960 --> 0:13:37.080
<v Speaker 2>So one of the things we've heard is that drugs

0:13:37.120 --> 0:13:40.080
<v Speaker 2>like spin rasa are incredibly expensive, and that part of

0:13:40.120 --> 0:13:42.439
<v Speaker 2>what seems to drive the price of these miracle drugs

0:13:42.559 --> 0:13:45.400
<v Speaker 2>is how much benefit they provide to the patient. But

0:13:45.480 --> 0:13:48.360
<v Speaker 2>what happens to the price when for some patients the

0:13:48.400 --> 0:13:51.880
<v Speaker 2>benefit is so much more than it is for other patients. So,

0:13:52.040 --> 0:13:56.320
<v Speaker 2>for example, patients who have milder forms of SMA, the

0:13:56.360 --> 0:13:59.720
<v Speaker 2>benefit might be less in comparison to patients who born

0:13:59.760 --> 0:14:01.320
<v Speaker 2>with the more severe forms.

0:14:01.960 --> 0:14:05.199
<v Speaker 4>This is the amazing quandary, and spinal must Gratupy shows

0:14:05.200 --> 0:14:08.440
<v Speaker 4>this more than anything, because the price is sort of

0:14:08.480 --> 0:14:10.240
<v Speaker 4>based upon the fact that a baby is going to

0:14:10.280 --> 0:14:14.920
<v Speaker 4>live and have a full and impactful life. And what's

0:14:14.960 --> 0:14:20.680
<v Speaker 4>that worth. Obviously it's worth everything. It's interesting that patients say,

0:14:20.760 --> 0:14:22.960
<v Speaker 4>I'm not getting better. I'm not like that kid, the

0:14:23.040 --> 0:14:25.280
<v Speaker 4>baby that got much better. I said, no, the baby's

0:14:25.280 --> 0:14:28.400
<v Speaker 4>getting better because we stopped degeneration at a time when

0:14:28.440 --> 0:14:31.880
<v Speaker 4>babies normally climb out of their mom's arms and run

0:14:31.920 --> 0:14:34.400
<v Speaker 4>around and then and develop and do normally. So we

0:14:34.480 --> 0:14:37.600
<v Speaker 4>allow that normal development to happen, But what's really happened

0:14:37.640 --> 0:14:40.800
<v Speaker 4>is we stopped degeneration. And so if we wait to

0:14:41.120 --> 0:14:44.640
<v Speaker 4>give the drug until after development has already accrued, they

0:14:44.680 --> 0:14:47.640
<v Speaker 4>actually are not getting better. They're just not declining any further.

0:14:48.280 --> 0:14:51.440
<v Speaker 4>And that's another place where the quandary between the insurance

0:14:51.480 --> 0:14:55.360
<v Speaker 4>providers and the doctors and the patients are in clash

0:14:55.520 --> 0:15:02.520
<v Speaker 4>because evidence is really hard to come by. Spinal weskiatvie

0:15:02.840 --> 0:15:06.760
<v Speaker 4>is going to be the story of many of the

0:15:06.800 --> 0:15:09.120
<v Speaker 4>diseases to come. So I think we can learn a

0:15:09.160 --> 0:15:13.920
<v Speaker 4>lot from what's happened so far, and this tension is

0:15:13.960 --> 0:15:17.120
<v Speaker 4>going to be a big issue in the next couple decades.

0:15:19.680 --> 0:15:22.120
<v Speaker 2>Tom, thank you so much for joining us today and

0:15:22.200 --> 0:15:26.560
<v Speaker 2>talking about this topic. Coming up after the break, we'll

0:15:26.560 --> 0:15:29.400
<v Speaker 2>hear more about how these miracle drugs are priced and

0:15:29.400 --> 0:15:44.040
<v Speaker 2>why accessing them is so difficult. Cheryl Yoda's experience of

0:15:44.080 --> 0:15:46.800
<v Speaker 2>getting insurance to cover the cost of her son Jas's

0:15:46.840 --> 0:15:51.200
<v Speaker 2>medicine is hardly typical. Holly Fernander's Lynch is a professor

0:15:51.240 --> 0:15:54.320
<v Speaker 2>of medical Ethics and Law at the University of Pennsylvania.

0:15:55.080 --> 0:16:00.200
<v Speaker 2>She focuses on access to investigational medicines, food and drug administration, policy,

0:16:00.560 --> 0:16:02.000
<v Speaker 2>and gatekeeping in healthcare.

0:16:03.440 --> 0:16:06.600
<v Speaker 3>I think equity is a huge challenge in this context.

0:16:06.720 --> 0:16:10.160
<v Speaker 3>So do you have insurance in the first place? How

0:16:10.360 --> 0:16:13.880
<v Speaker 3>high quality is the insurance coverage that you have access to.

0:16:14.520 --> 0:16:17.920
<v Speaker 3>But there's a lot of important data showing that even

0:16:18.040 --> 0:16:21.840
<v Speaker 3>people who have good insurance coverage are often unable to

0:16:22.040 --> 0:16:25.240
<v Speaker 3>access these high priced medicines because their out of pocket

0:16:25.280 --> 0:16:29.920
<v Speaker 3>costs are still so high. It's very few people who

0:16:29.920 --> 0:16:33.680
<v Speaker 3>can pay tens of thousands of dollars for a drug,

0:16:33.760 --> 0:16:35.840
<v Speaker 3>let alone, you know, the out of pocket costs for

0:16:35.880 --> 0:16:39.040
<v Speaker 3>a million dollar or two million dollar drug. So equity

0:16:39.120 --> 0:16:40.480
<v Speaker 3>is going to be a huge issue too.

0:16:41.120 --> 0:16:45.040
<v Speaker 2>The price point for spinras that seems shockingly high to me.

0:16:46.400 --> 0:16:49.400
<v Speaker 2>How do drug companies arrive at such high prices in

0:16:49.440 --> 0:16:50.160
<v Speaker 2>the first place.

0:16:51.200 --> 0:16:54.120
<v Speaker 3>So the way that you typically hear companies talking about

0:16:54.200 --> 0:16:57.360
<v Speaker 3>this is based on the research and development costs, what

0:16:57.440 --> 0:17:01.080
<v Speaker 3>it takes to actually bring these products to market. And

0:17:01.440 --> 0:17:04.080
<v Speaker 3>in that context, they're not thinking just about the drug

0:17:04.119 --> 0:17:07.040
<v Speaker 3>that ultimately got approved, but all the other drugs that

0:17:07.119 --> 0:17:11.360
<v Speaker 3>failed along the way before they got to human trials

0:17:11.560 --> 0:17:15.360
<v Speaker 3>or in earlier stages of clinical development, So that's certainly

0:17:15.480 --> 0:17:18.640
<v Speaker 3>part of it. However, there has been quite a bit

0:17:18.680 --> 0:17:21.760
<v Speaker 3>of research to demonstrate that it's not the R and

0:17:21.840 --> 0:17:26.119
<v Speaker 3>D prices that are dictating price that's actually set for

0:17:26.240 --> 0:17:31.439
<v Speaker 3>these drugs. It's market conditions. It's how much will the

0:17:31.480 --> 0:17:36.000
<v Speaker 3>market bear. What ultimately happens is that pharmaceutical companies get

0:17:36.040 --> 0:17:39.240
<v Speaker 3>to decide what the list price is going to be

0:17:39.280 --> 0:17:41.560
<v Speaker 3>for their drug. They come onto the market with very

0:17:41.640 --> 0:17:45.280
<v Speaker 3>high prices, and then payers have very little choice but

0:17:45.400 --> 0:17:47.280
<v Speaker 3>to pay those prices.

0:17:47.720 --> 0:17:50.439
<v Speaker 2>What about relative benefit, Well, the value of a drug.

0:17:50.920 --> 0:17:53.480
<v Speaker 2>Does that get taken into account when setting the price.

0:17:54.240 --> 0:17:59.120
<v Speaker 3>So value based pricing is really important. What impact are

0:17:59.160 --> 0:18:03.080
<v Speaker 3>these drugs having on people's lives? In many cases, the

0:18:03.160 --> 0:18:06.119
<v Speaker 3>drug price has no bearing on that. And that is

0:18:06.160 --> 0:18:10.720
<v Speaker 3>where we really run into ethical challenges because if a

0:18:10.840 --> 0:18:14.959
<v Speaker 3>drug is not very good, right, maybe it has a

0:18:14.960 --> 0:18:17.720
<v Speaker 3>marginal benefit, then we can say, look, we shouldn't be

0:18:17.760 --> 0:18:20.560
<v Speaker 3>paying high prices for that drug. But if a drug

0:18:20.600 --> 0:18:23.920
<v Speaker 3>is a cure for a life threatening disease, especially a

0:18:24.040 --> 0:18:27.520
<v Speaker 3>disease affecting children, the value is going to be really

0:18:27.600 --> 0:18:30.800
<v Speaker 3>high right, sometimes in the realm of millions of dollars,

0:18:30.880 --> 0:18:33.119
<v Speaker 3>and you might even say that those are cost effective

0:18:33.200 --> 0:18:36.119
<v Speaker 3>drugs because it's going to reduce the lifetime costs that

0:18:36.160 --> 0:18:38.959
<v Speaker 3>you might otherwise have to pay. So that's where those

0:18:39.000 --> 0:18:42.480
<v Speaker 3>are some of the most ethically challenging issues because their

0:18:42.480 --> 0:18:45.919
<v Speaker 3>cost effective, high value drugs. But if we had to

0:18:45.960 --> 0:18:48.600
<v Speaker 3>pay for them for a lot of patients, we won't

0:18:48.640 --> 0:18:50.879
<v Speaker 3>have enough money or resources to do that.

0:18:51.240 --> 0:18:53.480
<v Speaker 2>So we had earlier in the episode that the price

0:18:53.480 --> 0:18:56.159
<v Speaker 2>of spin Rouser was announced just after the drug was

0:18:56.160 --> 0:18:59.879
<v Speaker 2>approved by the FDA. Does the FDA approval process have

0:19:00.080 --> 0:19:01.760
<v Speaker 2>anything to do with the drug pricing?

0:19:02.359 --> 0:19:07.320
<v Speaker 3>They are completely disconnected. When FDA approves a drug, it

0:19:07.359 --> 0:19:12.520
<v Speaker 3>is evaluating only the safety and effectiveness of that drug.

0:19:13.320 --> 0:19:16.720
<v Speaker 3>It has nothing to do with price. It doesn't even

0:19:16.760 --> 0:19:18.960
<v Speaker 3>know what the price is because the price may not

0:19:19.040 --> 0:19:22.439
<v Speaker 3>be publicly announced. Yet even if it did know, it

0:19:22.480 --> 0:19:28.280
<v Speaker 3>could not take that into consideration. Once FDA approves a product,

0:19:28.640 --> 0:19:33.280
<v Speaker 3>then we get into questions about drug pricing and coverage,

0:19:33.720 --> 0:19:36.160
<v Speaker 3>and there's some debate about whether that's the right approach.

0:19:36.280 --> 0:19:38.119
<v Speaker 2>So could you talk a bit more about that debate?

0:19:38.359 --> 0:19:41.639
<v Speaker 2>What concerns does this rise from an ethics perspective.

0:19:41.640 --> 0:19:45.680
<v Speaker 3>Yeah, the debate largely has to do with whose responsibility

0:19:45.840 --> 0:19:50.400
<v Speaker 3>is it to consider price? And FDA is viewed as

0:19:50.440 --> 0:19:55.200
<v Speaker 3>a science based agency. Their expertise is evaluating clinical trial

0:19:55.320 --> 0:20:00.280
<v Speaker 3>data and evaluating is this drug strong enough that the

0:20:00.320 --> 0:20:04.040
<v Speaker 3>statutory standard has been met? Can we feel confident that

0:20:04.119 --> 0:20:07.639
<v Speaker 3>patients taking this drug the risk benefit ratio is going

0:20:07.680 --> 0:20:10.280
<v Speaker 3>to be reasonable for them. The product then goes on

0:20:10.359 --> 0:20:14.280
<v Speaker 3>the market, and if patients want to take it, then

0:20:14.440 --> 0:20:17.600
<v Speaker 3>they need to find some way of paying for it.

0:20:17.800 --> 0:20:21.080
<v Speaker 3>Many people will go to private insurance coverage to pay

0:20:21.560 --> 0:20:25.639
<v Speaker 3>Lots of people are covered through government programs. Sometimes what

0:20:25.680 --> 0:20:28.240
<v Speaker 3>you see happening is for these very high priced drugs,

0:20:28.280 --> 0:20:31.880
<v Speaker 3>even if people have insurance coverage, they are crowd funding

0:20:32.280 --> 0:20:36.280
<v Speaker 3>to pay for the out of pocket costs. And that's

0:20:36.320 --> 0:20:38.400
<v Speaker 3>when you get people, you know, kind of pulling their

0:20:38.440 --> 0:20:41.320
<v Speaker 3>hair out, like, how could it be in this highly

0:20:41.359 --> 0:20:45.080
<v Speaker 3>privileged nation, we're asking people to go on the internet

0:20:45.200 --> 0:20:48.040
<v Speaker 3>and ask their friends and family for money to pay

0:20:48.119 --> 0:20:53.040
<v Speaker 3>for maybe life saving products, but certainly life affecting products.

0:20:53.119 --> 0:20:56.520
<v Speaker 2>So can any federal agency set limits on drug pricing?

0:20:57.080 --> 0:21:00.680
<v Speaker 3>There are lots of federal payers that are involved in coverage.

0:21:00.720 --> 0:21:05.480
<v Speaker 3>So we have Medicare, Medicaid, and then the Veterans Administration,

0:21:05.800 --> 0:21:08.320
<v Speaker 3>and they all are a bit different in what their

0:21:08.359 --> 0:21:12.000
<v Speaker 3>statutory authority allows them to do. So you may have

0:21:12.119 --> 0:21:15.800
<v Speaker 3>heard about the Inflation Reduction Act. It's a huge piece

0:21:15.800 --> 0:21:18.960
<v Speaker 3>of legislation that has lots of components to it, two

0:21:19.000 --> 0:21:22.440
<v Speaker 3>of which have to do with drug pricing. So for

0:21:22.480 --> 0:21:28.679
<v Speaker 3>a very long time, Medicare was not allowed to negotiate price.

0:21:29.359 --> 0:21:31.680
<v Speaker 3>So FDA would say this drug is safe and effective.

0:21:32.160 --> 0:21:35.480
<v Speaker 3>Then Medicare had a decision to make is this drug

0:21:35.640 --> 0:21:40.120
<v Speaker 3>reasonable and necessary for the Medicare population. So Medicare can

0:21:40.160 --> 0:21:44.680
<v Speaker 3>say it's not reasonable and necessary or it is. They

0:21:44.680 --> 0:21:46.760
<v Speaker 3>have an on off switch, are we going to cover

0:21:46.840 --> 0:21:51.359
<v Speaker 3>it or not? But they can't consider cost or cost effectiveness,

0:21:51.400 --> 0:21:55.800
<v Speaker 3>so they couldn't negotiate for prices. Under the Inflation Reduction Act,

0:21:56.280 --> 0:22:00.359
<v Speaker 3>for the first time, Medicare has the ability to start

0:22:00.400 --> 0:22:04.439
<v Speaker 3>negotiating prices on a very limited set of drugs. To

0:22:04.560 --> 0:22:08.640
<v Speaker 3>start off with, do you basically have nine to thirteen

0:22:08.720 --> 0:22:11.320
<v Speaker 3>years as a drug company to profit as much as

0:22:11.359 --> 0:22:14.439
<v Speaker 3>you want before Medicare could negotiate the price. There are

0:22:14.440 --> 0:22:18.200
<v Speaker 3>some other exclusions for drugs, for rare diseases, for example.

0:22:18.960 --> 0:22:22.360
<v Speaker 3>But this is a big development. Medicare will negotiate prices

0:22:22.359 --> 0:22:27.080
<v Speaker 3>on those ten drugs, and then every year thereafter additional

0:22:27.160 --> 0:22:30.119
<v Speaker 3>drugs will kind of get added to the negotiation list.

0:22:30.480 --> 0:22:32.600
<v Speaker 2>And so we hear these stories about people that have

0:22:32.680 --> 0:22:36.359
<v Speaker 2>to fight their insurance companies in the US to get

0:22:36.400 --> 0:22:41.480
<v Speaker 2>expensive treatment covered, and there's some varying outcomes. Is there

0:22:41.520 --> 0:22:45.120
<v Speaker 2>a rhymal reason to this when the decisions are made?

0:22:45.600 --> 0:22:49.960
<v Speaker 3>So, what insurance companies are typically doing is evaluating whether

0:22:50.000 --> 0:22:54.720
<v Speaker 3>a drug is medically necessary, and that might be a

0:22:54.760 --> 0:23:00.119
<v Speaker 3>little bit different than the broad label or indication for

0:23:00.160 --> 0:23:04.040
<v Speaker 3>which FDA approves a drug. So sometimes FDA will approve

0:23:04.040 --> 0:23:07.320
<v Speaker 3>a drug for a very narrow population children up to

0:23:07.359 --> 0:23:11.080
<v Speaker 3>age two, for example. Sometimes though FDA gives a very

0:23:11.080 --> 0:23:15.320
<v Speaker 3>broad indication, you know, people with early stage dementia or

0:23:15.359 --> 0:23:19.159
<v Speaker 3>Alzheimer's disease, for example. And so part of what the

0:23:19.200 --> 0:23:23.080
<v Speaker 3>insurance company has to do is evaluate is there some

0:23:23.320 --> 0:23:27.520
<v Speaker 3>more narrow population for which this FDA approved drug is

0:23:27.520 --> 0:23:32.320
<v Speaker 3>going to truly be medically necessary. Sometimes insurers will say

0:23:32.800 --> 0:23:35.840
<v Speaker 3>you need to have prior authorization, so we want your

0:23:35.960 --> 0:23:39.360
<v Speaker 3>doctor to talk to our insurance company doctors to make

0:23:39.400 --> 0:23:43.200
<v Speaker 3>sure that you can access the drug. Sometimes they will

0:23:43.840 --> 0:23:47.640
<v Speaker 3>make you try other drugs first, but in many cases,

0:23:47.760 --> 0:23:50.680
<v Speaker 3>the drugs that are getting approved are the only thing

0:23:51.119 --> 0:23:56.840
<v Speaker 3>for the disease or condition in question. It's this or nothing.

0:23:57.160 --> 0:24:01.280
<v Speaker 3>And so sometimes we do see insurance company denying access

0:24:01.400 --> 0:24:05.240
<v Speaker 3>to patients because they say it's not medically necessary, and

0:24:05.280 --> 0:24:08.080
<v Speaker 3>then you get into appeals where you know the patient's

0:24:08.080 --> 0:24:10.280
<v Speaker 3>physician will go to the company and say no, it

0:24:10.320 --> 0:24:13.720
<v Speaker 3>really is medically necessary. But of course that takes time

0:24:13.920 --> 0:24:17.520
<v Speaker 3>and resources to go back and forth. It is important

0:24:17.800 --> 0:24:21.840
<v Speaker 3>for insurers to be able to carefully evaluate should we

0:24:22.000 --> 0:24:25.360
<v Speaker 3>be paying this price for this drug for this patient,

0:24:25.880 --> 0:24:28.679
<v Speaker 3>because if they don't carefully analyze that, they're going to

0:24:28.720 --> 0:24:31.840
<v Speaker 3>run out of resources for their pool. The question is,

0:24:32.000 --> 0:24:33.920
<v Speaker 3>you know, how far do they need to go in

0:24:34.040 --> 0:24:35.000
<v Speaker 3>that regard.

0:24:35.240 --> 0:24:38.520
<v Speaker 2>So you've been talking about the US so far. How

0:24:38.600 --> 0:24:42.360
<v Speaker 2>are these issues addressed outside the US and what different

0:24:42.680 --> 0:24:45.800
<v Speaker 2>essical issues to these approaches raise.

0:24:46.600 --> 0:24:49.800
<v Speaker 3>Yeah, there's two big differences between the US and elsewhere.

0:24:50.359 --> 0:24:53.959
<v Speaker 3>In the US, we have private health insurance system that

0:24:54.119 --> 0:24:57.720
<v Speaker 3>runs alongside public health insurance, right, so a lot of

0:24:57.760 --> 0:25:01.119
<v Speaker 3>Americans get their coverage through their owls lawyers, and we

0:25:01.200 --> 0:25:04.919
<v Speaker 3>have lots of different insurers. Outside the US, right we

0:25:04.960 --> 0:25:09.480
<v Speaker 3>see more typically national health systems and national health insurance

0:25:09.560 --> 0:25:12.480
<v Speaker 3>provided by the government to the citizens. And then you

0:25:12.600 --> 0:25:17.080
<v Speaker 3>have the government decide is this drug worth paying for

0:25:17.520 --> 0:25:19.600
<v Speaker 3>and how much are we going to pay for it?

0:25:20.040 --> 0:25:22.520
<v Speaker 3>And there's pros and cons to that. So in the US,

0:25:23.040 --> 0:25:25.600
<v Speaker 3>once a FDA approves a drug, if you can find

0:25:25.640 --> 0:25:28.280
<v Speaker 3>a way to pay for it, there's no waiting. You

0:25:28.280 --> 0:25:32.399
<v Speaker 3>could gain access to it the very next day. Elsewhere

0:25:32.760 --> 0:25:37.159
<v Speaker 3>there can be a pretty substantial lag in between regulatory

0:25:37.200 --> 0:25:40.159
<v Speaker 3>approval for the drug and when patients are going to

0:25:40.200 --> 0:25:42.800
<v Speaker 3>access it because the government has to decide whether it's

0:25:42.840 --> 0:25:45.760
<v Speaker 3>going to pay. But the pro is that it is

0:25:46.080 --> 0:25:49.400
<v Speaker 3>a wiser use of resources because then the government is

0:25:49.520 --> 0:25:52.040
<v Speaker 3>negotiating with a company, here's how much we think your

0:25:52.040 --> 0:25:56.440
<v Speaker 3>product is worth. It's a stronger stewardship of healthcare resources

0:25:56.480 --> 0:25:58.520
<v Speaker 3>for the government to say this is what this product

0:25:58.560 --> 0:26:00.199
<v Speaker 3>is worth, and this is all we're going on to

0:26:00.200 --> 0:26:02.879
<v Speaker 3>be willing to pay. And that's really important because we

0:26:02.920 --> 0:26:07.199
<v Speaker 3>don't have unlimited resources in any capacity, let alone unlimited

0:26:07.359 --> 0:26:09.879
<v Speaker 3>money to pay for medicines.

0:26:11.640 --> 0:26:14.800
<v Speaker 2>Could you tell us how big an issue you think

0:26:14.840 --> 0:26:16.679
<v Speaker 2>this is likely to be in the coming years.

0:26:17.480 --> 0:26:21.480
<v Speaker 3>So you know, if it's spinal muscular atrophy, it's affecting

0:26:21.920 --> 0:26:25.760
<v Speaker 3>deeply affecting, but affecting us proportionately small part of the population,

0:26:26.640 --> 0:26:30.520
<v Speaker 3>and so you can find ways to cover very high

0:26:30.520 --> 0:26:37.200
<v Speaker 3>priced products because it's spread over a broader population that's paying.

0:26:37.359 --> 0:26:40.520
<v Speaker 3>But once you start to have drugs that are very

0:26:40.520 --> 0:26:44.160
<v Speaker 3>effective for terrible diseases that affect a much wider part

0:26:44.200 --> 0:26:46.960
<v Speaker 3>of the population, you're not going to be able to

0:26:46.960 --> 0:26:49.399
<v Speaker 3>fudge your way through it the way you can with

0:26:49.600 --> 0:26:52.080
<v Speaker 3>rare disease. And then we're really going to have to

0:26:52.119 --> 0:26:56.440
<v Speaker 3>face the music to say these drugs are important, they're

0:26:56.440 --> 0:26:59.840
<v Speaker 3>cost effective, but they're hugely expensive. Are we going to

0:26:59.840 --> 0:27:01.639
<v Speaker 3>pay for this or are we going to pay for

0:27:01.720 --> 0:27:05.399
<v Speaker 3>something else that's important to a functional society?

0:27:05.680 --> 0:27:07.840
<v Speaker 2>Yeah, I mean, how do you think we should navigate

0:27:07.880 --> 0:27:08.879
<v Speaker 2>these kind of questions?

0:27:09.280 --> 0:27:11.560
<v Speaker 3>This is what ethicists work on all the time. These

0:27:11.560 --> 0:27:15.600
<v Speaker 3>are career spanning ethical challenges, trying to come up with

0:27:15.640 --> 0:27:18.760
<v Speaker 3>the best arguments for one approach or another. There's not

0:27:18.840 --> 0:27:21.680
<v Speaker 3>a clear cut response to say this is the right

0:27:21.720 --> 0:27:23.920
<v Speaker 3>way to spend our money, this is the wrong way

0:27:24.960 --> 0:27:30.000
<v Speaker 3>in the US at least, this has been politicized in

0:27:30.000 --> 0:27:35.360
<v Speaker 3>a really terrible way. The minute you start talking about

0:27:35.440 --> 0:27:41.840
<v Speaker 3>not covering things, there are claims of government death panels

0:27:42.240 --> 0:27:47.000
<v Speaker 3>that are going to put a price on life, and

0:27:47.080 --> 0:27:49.679
<v Speaker 3>who wants to live in a world like that. On

0:27:49.760 --> 0:27:52.800
<v Speaker 3>the other hand, that completely fails to recognize that we

0:27:52.880 --> 0:27:55.199
<v Speaker 3>have to make judgments about how we're going to spend

0:27:55.320 --> 0:28:00.760
<v Speaker 3>our resources, and it's reasonable to ask, even if it's

0:28:00.800 --> 0:28:04.479
<v Speaker 3>life saving, how much does something cost? Can we afford it?

0:28:04.520 --> 0:28:08.160
<v Speaker 3>And what's the trade off? Very often, if something's life saving,

0:28:09.080 --> 0:28:11.000
<v Speaker 3>people are going to be willing to accept that trade off.

0:28:11.040 --> 0:28:13.199
<v Speaker 3>Right the community is going to be willing to accept

0:28:13.240 --> 0:28:15.600
<v Speaker 3>that trade off. But we can't stick our head in

0:28:15.600 --> 0:28:19.080
<v Speaker 3>the sand and pretend like we have unlimited resources because

0:28:19.080 --> 0:28:20.960
<v Speaker 3>we don't.

0:28:21.840 --> 0:28:24.960
<v Speaker 2>Cheryl Yoda is beyond grateful that a drug was developed

0:28:25.000 --> 0:28:28.640
<v Speaker 2>in time to save her son Jayce's life, especially when

0:28:28.760 --> 0:28:32.840
<v Speaker 2>so many other less rare diseases need funding to But

0:28:32.920 --> 0:28:36.480
<v Speaker 2>does that mean she thinks Spinaza's price is fair? She says,

0:28:36.480 --> 0:28:37.800
<v Speaker 2>the answer isn't so simple.

0:28:38.480 --> 0:28:41.000
<v Speaker 1>What is a good price, or like, what would be

0:28:41.000 --> 0:28:44.000
<v Speaker 1>a reasonable cost? I have no idea, like I don't

0:28:44.000 --> 0:28:46.719
<v Speaker 1>feel like I know. I mean, that's the whole question.

0:28:48.440 --> 0:28:51.160
<v Speaker 2>She says, She's been so fortunate already that it would

0:28:51.160 --> 0:28:54.040
<v Speaker 2>feel almost selfish to hope that the drug's price would

0:28:54.040 --> 0:28:58.200
<v Speaker 2>come down to her. Calling Spinaza a miracle drug isn't

0:28:58.200 --> 0:29:01.960
<v Speaker 2>an exaggeration, but still she can't help but dream of

0:29:02.000 --> 0:29:04.040
<v Speaker 2>a day when it's more easily accessible.

0:29:04.760 --> 0:29:08.320
<v Speaker 1>I know that the science that goes into making it

0:29:08.360 --> 0:29:12.240
<v Speaker 1>is still pretty complicated, but the more they know about

0:29:12.240 --> 0:29:14.640
<v Speaker 1>it and the longer they're making it, they get better

0:29:14.680 --> 0:29:17.440
<v Speaker 1>at it or easier, and it wouldn't have to be

0:29:17.480 --> 0:29:28.280
<v Speaker 1>so expensive. It's a good dream.

0:29:28.560 --> 0:29:31.680
<v Speaker 2>Next time on Playing God, we look into the future

0:29:31.920 --> 0:29:35.320
<v Speaker 2>to learn more about a technology that would create human

0:29:35.360 --> 0:29:39.440
<v Speaker 2>babies without starting with sperm or eggs. It's a long

0:29:39.480 --> 0:29:42.719
<v Speaker 2>way off, but researchers and biotech companies are already at

0:29:42.760 --> 0:29:46.600
<v Speaker 2>work or making this possible. If they succeed, it would

0:29:46.640 --> 0:29:49.120
<v Speaker 2>open up a whole world of new options for how

0:29:49.200 --> 0:29:53.240
<v Speaker 2>humans procreate. But how can we be sure this technology

0:29:53.320 --> 0:29:58.040
<v Speaker 2>is introduced safely and ethically. That's next time on Playing God.

0:30:01.840 --> 0:30:06.280
<v Speaker 2>Thank you to our guests Cheryl Yoder, Holly Fernandez Lynch,

0:30:06.800 --> 0:30:11.480
<v Speaker 2>and Tom Crawford. Playing God is a co production of

0:30:11.560 --> 0:30:15.080
<v Speaker 2>Pushkin Industries and the Berman Institute of Bioethics at Johns

0:30:15.120 --> 0:30:20.240
<v Speaker 2>Hopkins University. Emily Vaughan is our lead producer. This episode

0:30:20.400 --> 0:30:24.360
<v Speaker 2>was also produced by Sophie Crane and Lucy Sullivan. Our

0:30:24.480 --> 0:30:29.320
<v Speaker 2>editors are Karen Shakergee and Kate Parkinson Morgan. Mixing by

0:30:29.360 --> 0:30:34.280
<v Speaker 2>Samir Sengupta, the music by Echo Mountain, Engineering support from

0:30:34.320 --> 0:30:39.480
<v Speaker 2>Sarah Brugare and Amanda ka Wang. Show art by Sean Carney,

0:30:40.480 --> 0:30:45.200
<v Speaker 2>fact checking by David jar and Arthur Gompertz. Our executive

0:30:45.240 --> 0:30:50.960
<v Speaker 2>producer is Justine Lang at the Johns Hopkins Berman Institute

0:30:50.960 --> 0:30:55.400
<v Speaker 2>of Bioethics. Our executive producers are Jeffrey Kahan and Anna Mastriani,

0:30:55.880 --> 0:31:01.040
<v Speaker 2>working with Emilia Hood. Specials thanks to Jared Whyland. Funding

0:31:01.080 --> 0:31:05.760
<v Speaker 2>provided by the Greenwall Foundation. I'm Laurena Rura Hutchinson. Come

0:31:05.760 --> 0:31:19.360
<v Speaker 2>back next week for more Playing God. Has this show

0:31:19.400 --> 0:31:23.640
<v Speaker 2>inspired you? Are you interested in studying bioethics? Perhaps you

0:31:23.680 --> 0:31:26.680
<v Speaker 2>want to become someone shaping this field. We have a

0:31:26.760 --> 0:31:30.240
<v Speaker 2>Master of Bioethics program at the Johns Hopkins Berman Institute

0:31:30.240 --> 0:31:34.840
<v Speaker 2>of Bioethics. To find out more, visit Bioethics dot Jhu

0:31:35.000 --> 0:31:39.400
<v Speaker 2>dot edu. Forward slash MBE scholarships are available.